论文部分内容阅读
【目的】探讨肿瘤型M2丙酮酸激酶（TumortypeM2-pyruvatekinase，TUM2-PK）在膀胱癌中的表达及临床意义分析。【方法】采取2009年1月至2012年1月，221例膀胱癌患者和220例健康正常人的血清标本，应用酶联免疫吸附测定法（ELISA）定量检测标本的TUM2-PK水平，研究试验组与对照组，以及病理分型与TUM2-PK关系。【结果】膀胱癌患者血清中TUM2-PK的含量明显高于正常对照组[（39．4±3．5）u/mLvs（7．3±2．1）u/mL（P＜0．05）]；同时根据膀胱癌病理分级TUM2-PK的含量存在一定差异：T1期（32．1±6．1）u/mL，T2期（34．1±4．3）u/mL，T3期（68．2±5．9）u/mL。T1期膀胱癌与T2期膀胱癌TUM2-PK含量无明显差异，但T3期较T1、T2明显增高。【结论】监测血清中TUM2-PK含量有助于膀胱肿瘤的早期诊断，同时根据TUM2-PK的含量亦可作为监测肿瘤及疾病分级的重要手段之一。“,”[Objective]To explore the expression of tumor type M2-pyruvate kinase(Tu M2-PK) in bladder cancer and its clinical significance .[Methods] Serum samples of 221 patients with bladder cancer and 220 healthy normal people from Jan .2009 to Jan .2012 were collected .Serum level of Tu M2-PK was detected by ELISA ,and compared between experimental group and control group .The correlation between Tu M2-PK and pathological type was analyzed .[Results]Serum levels of Tu M2-PK in patients with bladder cancer were ob-viously higher than those in control group[(39 .4 ± 3 .5)u/mL vs (7 .3 ± 2 .1)u/mL ,P <0 .05)] .There was significant difference in Tu M2-PK level among different pathological stages of bladder cancer .Tu M2-PK lev-els in stage T1 ,T2 and T3 were (32 .1 ± 6 .1)u/mL ,(34 .1 ± 4 .3)u/mL and (68 .2 ± 5 .9)u/mL ,respectively . There was no significant difference in Tu M2-PK level between stage T1 and stage T2 .Compared with stage T1 and T2 ,Tu M2-PK levels in stage T3 were increased obviously .[Conclusion] The monitoring of serum Tu M2-PK is helpful for the early diagnosis of bladder cancer .Meanwhile Tu M2-PK level can be also used as an important means for the monitoring and grading of the tumor .